title: Pharmacokinetics, Safety and Tolerability of Single Oral or Intravenous Administration of 200 mg Tedizolid Phosphate in Adolescents.
abstract: Tedizolid is a novel oxazolidinone antibacterial US FDA approved for treatment of acute bacterial skin and skin structure infections in adults. This study assessed the pharmacokinetics, safety and tolerability of tedizolid phosphate in adolescents (12-17 years old) after administration of a single intravenous (IV) or oral dose.
  
  
  
  In this multicenter, open-label study, a single IV infusion (N = 10) or oral dose (N = 10) of 200 mg tedizolid phosphate was administered to adolescents already receiving antibacterial treatment for presumed or documented infection. Blood and urine samples were collected predose and over 24 hours.
  
  
  
  Tedizolid pharmacokinetics was generally similar after IV or oral administration of 200 mg tedizolid phosphate. Mean (standard deviation) half-life values were similar for oral and IV routes, 8.3 (2.0) and 6.6 (0.7) hours, respectively. Absolute oral bioavailability of tedizolid (90% confidence interval) was 88.8% (70.4%-112.1%). Geometric mean ratio (90% confidence interval) of area under the concentration-time curve values for adolescents relative to values previously reported for adults after 200 mg of single-dose IV or oral administration were 0.847 (0.736-0.975). Tedizolid was well tolerated.
  
  
  
  Overall pharmacokinetics of tedizolid was similar after administration of a single oral or IV 200 mg dose, and bioavailability was high. Exposure profiles were similar to those in adults. With clinical outcomes based on area under the concentration-time curve/minimum inhibitory concentration and current susceptibility of Gram-positive pathogens, results suggest that the 200 mg daily regimen of tedizolid phosphate can be extended to adolescents for clinical trials, and that dose adjustment may not be required when switching routes.
authors.affiliation: From the *Department of Pediatrics, University of California, San Diego, California; †Rady Children's Hospital, San Diego, California; ‡Clinical Development Merck & Co., Inc., Kenilworth, New Jersey; §Division of Infectious Diseases Children's Hospital of Orange County, Orange California; and ¶Department of Pediatrics, Arkansas Children's Hospital, Little Rock, Arkansas.
authors.forename: John S
authors.initials: JS
authors.lastname: Bradley
authors.forename: Shawn D
authors.initials: SD
authors.lastname: Flanagan
authors.forename: Antonio C
authors.initials: AC
authors.lastname: Arrieta
authors.forename: Richard
authors.initials: R
authors.lastname: Jacobs
authors.forename: Edmund
authors.initials: E
authors.lastname: Capparelli
authors.forename: Philippe
authors.initials: P
authors.lastname: Prokocimer
mesh_terms: D061605:Administration, Intravenous; D000284:Administration, Oral; D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*; D001424:Bacterial Infections / Q000188:drug therapy*; D001682:Biological Availability; D001774:Blood Chemical Analysis; D002648:Child; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology*; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D010755:Organophosphates / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*; D010080:Oxazoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*; D014556:Urine / Q000737:chemistry
chemical_list: D000900:Anti-Bacterial Agents; D010755:Organophosphates; D010080:Oxazoles; C515040:tedizolid phosphate